Rituximab (Mabthera) for treatment of rare autoimmune bullous skin disorders
Autoimmune bullous skin disorders are characterized by a severe and potentially lethal course and may require aggressive long-term treatment with systemic corticosteroids and other immunosuppressive drugs, which can lead to serious adverse events. Recently, anti-CD20 antibody, Rituximab, was reported to be beneficial as an adjuvant therapy in these diseases. Herein, we present 2 case reports of patients suffering from resistant rare diseases from the aforementioned spectrum: linear IgA dermatosis and Pemphigoid gestationis. The patients were successfully treated with Rituximab (Mabthera). This is one of the first reports of this kind of treatment for these rare life-threatening diseases. These case reports emphasize the role of Rituximab as a crisis therapy in autoimmune blistering diseases.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:151 |
|---|---|
| Enthalten in: |
Harefuah - 151(2012), 10 vom: 01. Okt., Seite 562-5, 606 |
| Sprache: |
Hebräisch |
|---|
| Beteiligte Personen: |
Lozinski, Alina [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 15.02.2013 Date Revised 19.11.2015 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM224147676 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM224147676 | ||
| 003 | DE-627 | ||
| 005 | 20231224062257.0 | ||
| 007 | tu | ||
| 008 | 231224s2012 xx ||||| 00| ||heb c | ||
| 028 | 5 | 2 | |a pubmed24n0747.xml |
| 035 | |a (DE-627)NLM224147676 | ||
| 035 | |a (NLM)23316661 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a heb | ||
| 100 | 1 | |a Lozinski, Alina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rituximab (Mabthera) for treatment of rare autoimmune bullous skin disorders |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 15.02.2013 | ||
| 500 | |a Date Revised 19.11.2015 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Autoimmune bullous skin disorders are characterized by a severe and potentially lethal course and may require aggressive long-term treatment with systemic corticosteroids and other immunosuppressive drugs, which can lead to serious adverse events. Recently, anti-CD20 antibody, Rituximab, was reported to be beneficial as an adjuvant therapy in these diseases. Herein, we present 2 case reports of patients suffering from resistant rare diseases from the aforementioned spectrum: linear IgA dermatosis and Pemphigoid gestationis. The patients were successfully treated with Rituximab (Mabthera). This is one of the first reports of this kind of treatment for these rare life-threatening diseases. These case reports emphasize the role of Rituximab as a crisis therapy in autoimmune blistering diseases | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Anti-Infective Agents |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Murine-Derived |2 NLM | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 650 | 7 | |a Dapsone |2 NLM | |
| 650 | 7 | |a 8W5C518302 |2 NLM | |
| 650 | 7 | |a Prednisone |2 NLM | |
| 650 | 7 | |a VB0R961HZT |2 NLM | |
| 700 | 1 | |a Baum, Sharon |e verfasserin |4 aut | |
| 700 | 1 | |a Sagi, Lior |e verfasserin |4 aut | |
| 700 | 1 | |a Volkov, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Trau, Henri |e verfasserin |4 aut | |
| 700 | 1 | |a Barzilai, Aviv |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Harefuah |d 1946 |g 151(2012), 10 vom: 01. Okt., Seite 562-5, 606 |w (DE-627)NLM000070491 |x 0017-7768 |7 nnns |
| 773 | 1 | 8 | |g volume:151 |g year:2012 |g number:10 |g day:01 |g month:10 |g pages:562-5, 606 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 151 |j 2012 |e 10 |b 01 |c 10 |h 562-5, 606 | ||